MLI Certified

On-Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
Lessons Learned from Your Patient's Family After Their Loved One Has Died
Our time spent with patients and their families should not end with the transfer of the patient to hospice care. The patient may even resist such a transfer, feeling abandoned by their medical oncology team. Treatment for treatment’s sake is really bad medical care. Doing an effective job of preparing the patient and family for end of life needs to be the ultimate goal as treatments begin to no longer work. Due to having no contact with families after the patients have died results in losing teaching moments for the team that provided her breast cancer treatment. There is great value in incorporating the family’s needs and understanding into the treatment planning process from the beginning so they are better prepared at the end of her life and beyond.
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Scroll to Top